What were Kymera Therapeutics' Q1 2026 revenues?

The exact figure was not disclosed, but it exceeded analyst estimates, driven by the Gilead collaboration.

How did Kymera's stock perform after the announcement?

Shares rose modestly in after-hours trading, limited by the lack of detailed financials.

Is the Gilead collaboration a key revenue driver for Kymera?

Yes, the Gilead collaboration is the primary revenue driver, contributing a significant portion of Q1 revenue.

Kymera Therapeutics Q1 2026 Revenue Beats on Gilead Collaboration

Q: Did the KT-200 deal impact Kymera's results?

Yes, Kymera received a milestone payment from the KT-200 deal, boosting revenue and cash flow.

Kymera Therapeutics topped Q1 revenue estimates on strong Gilead collaboration. The KT-200 milestone deal also boosted the outlook as pipeline advances.

Kymera Therapeutics (KYMR) reported its first-quarter 2026 financial results, beating revenue estimates thanks to its ongoing collaboration with Gilead Sciences (GILD). The strong performance was also supported by a milestone payment from the KT-200 program and progress in its pipeline.

Key Financial Results

Metric	Q1 2026	Estimate	Difference
Revenue	Not disclosed	Above consensus	Positive
EPS	Not disclosed	—	—
Collaboration revenue	Significant portion	—	—

Note: Exact figures were not provided by the company.

Highlights from the Release

Kymera stated that the Gilead collaboration was the primary revenue driver, with continued progress in joint programs. The company also received a milestone payment from the KT-200 deal, boosting cash flow and funding research.

Future Guidance

Kymera did not issue specific quarterly guidance but emphasized pipeline progress and plans to expand the Gilead collaboration.

Stock Impact

Kymera shares rose in after-hours trading following the announcement, though the move was limited due to the lack of detailed financials.

What This Means for Investors

Kymera's performance underscores the strength of its Gilead collaboration as a key revenue pillar. However, the absence of full financial details limits precise valuation. Investors should watch upcoming reports to assess growth sustainability.